In partnership with
You have probably heard the name Ozempic by now. You may have heard Wegovy, Mounjaro, or Zepbound. You might have a friend who started one of these and lost weight faster than anything they had ever tried before, or you have seen the headlines and the debates online and walked away more confused than when you started. What almost nobody is doing is slowing down long enough to explain what these compounds actually are, where they came from, and why each new version hits harder than the one before it. There are three compounds at the center of this conversation: Semaglutide, Tirzepatide, and Retatrutide and they are not three competing products. They are three generations of the same discovery; each one built directly on top of what came before it and understanding the difference between them is not complicated once someone walks you through it without trying to sell you something.
What Your Body Is Already Doing
Your body already produces a hormone called GLP-1 every time you eat. It tells your pancreas to release insulin, sends a fullness signal to your brain, and slows digestion so energy is absorbed gradually rather than all at once. For many people this system does not fire the way it should, and hunger does not quiet down, blood sugar spikes, and the fullness signal arrives too late. This is not a willpower problem, it’s a signaling problem, and these three compounds exist to fix it. Each one mimics GLP-1 but was engineered to survive in the body far longer than the two to three minutes your natural version lasts, and each generation expanded on the one before it by adding more receptor targets to the same core idea.
Generation One: Semaglutide
The compound that proved the concept and then surprised everyone with what else it could do.
Semaglutide mimics GLP-1 and was engineered to last approximately seven days in the body, which is what makes a once-weekly injection possible. The STEP trials the large human studies that established semaglutide for obesity showed participants losing an average of 13% to 15% of their total body weight over 68 weeks. For someone weighing 220lbs, that is roughly 30lbs to 32lbs. The results were consistent across different populations, different starting weights, and different levels of existing health complications, which gave the research community confidence that the effect was real and repeatable.
What nobody anticipated was how far the research would reach beyond weight. The SELECT trial followed over 17,000 people with obesity and existing heart disease and found that semaglutide reduced the risk of major cardiovascular events, heart attacks, strokes, and cardiovascular death by 20% over a multi-year follow-up. The FLOW trial found semaglutide slowing the progression of chronic kidney disease and reducing major kidney events by 24% in high-risk diabetic patients. A drug approved for a metabolic condition was quietly generating meaningful data across organ systems that researchers had not originally set out to study. Side effects are primarily nausea and digestive discomfort during early dose escalation, front-loaded for most people and manageable as the body adjusts, though a smaller number of people do not tolerate the GI effects at any dose.
Semaglutide activates one receptor and does it well. But researchers were already testing what would happen when you activated two at the same time and what came back forced people to reconsider what they thought they understood.
Generation Two: Tirzepatide
Two receptors instead of one. The head-to-head trial results just published and the gap was bigger than almost anyone predicted.
Tirzepatide activates GLP-1 and a second receptor called GIP, which stands for Glucose-dependent Insulinotropic Polypeptide. GIP is another hormone your gut naturally produces after eating, operating through a completely separate pathway with its own effects on insulin, fat storage, and energy distribution. Researchers theorized that combining both signals in a single molecule would produce results neither could achieve alone. The SURMOUNT-5 trial was designed to test that theory head-to-head, and it delivered a decisive answer.
Published in the New England Journal of Medicine in May 2025, SURMOUNT-5 enrolled over 700 people with obesity and ran for 72 weeks. Tirzepatide produced average weight loss of 20.2%. Semaglutide produced 13.7%. That 6.5% gap translates to roughly 14 additional pounds for someone starting at 220lbs just from adding one more receptor. Women in the trial on tirzepatide lost 23.8% compared to 18% on semaglutide. The proportion of participants reaching the 15% weight loss threshold considered clinically meaningful for long-term cardiovascular risk reduction was substantially higher in the tirzepatide group across every subpopulation analyzed.
The SURPASS trials added the diabetes picture. Participants achieved HbA1c reductions of up to 2.4% more than double what most diabetes medications are considered effective at producing while simultaneously losing substantial weight, creating a reinforcing cycle of metabolic improvement that the trial data captured across multiple measured outcomes. Tirzepatide costs more than semaglutide, access varies, and side effect tolerance is individual. What is not debatable is what SURMOUNT-5 showed: the head-to-head trial ran, the data was published, and tirzepatide won by a margin larger than most expected.
Generation Three: Retatrutide
Three receptors. Not yet approved. The Phase 3 trial just reported results that researchers are calling surgical-level. This is what is coming next.
Retatrutide adds a third receptor glucagon to the GLP-1 and GIP activation that tirzepatide already provides. Most people know glucagon as the hormone that raises blood sugar, but its second function is what matters here: when the glucagon receptor is activated alongside GLP-1 and GIP, the liver shifts into an accelerated state of fat burning, pulling stored fat from tissue and breaking it down for energy at a rate no prior non-surgical intervention had reliably produced. That triple activation creates a metabolic environment in the body that researchers had theorized about but never been able to consistently measure in human beings until the TRIUMPH-1 trial results arrived in May 2026.
Those results stopped people mid-conversation. Participants on the 12mg dose lost an average of 70.3lbs which is 28.3% of their total body weight over 8 weeks. At one 104 weeks the average reached 30.3% and 45.3% of participants in the highest dose group lost 30% or more of their body weight. Nearly half of the people in the trial lost nearly a third of themselves. Physicians and researchers began reaching for a comparison that is rarely used in a pharmacological context: bariatric surgery, which typically produces 25% to 30% total weight loss over 1 to 2 years. Retatrutide, in TRIUMPH-1, was not approaching surgical outcomes. It was matching and in a significant proportion of participants exceeding them, without any procedure.
The Phase 2 data published in Nature Medicine in 2024 had already shown 24.2% average weight loss at 48 weeks higher than semaglutide's entire STEP program. What Phase 3 confirmed was that those results held at scale and that the weight loss continued compounding over time rather than plateauing the way earlier generations tended to. Retatrutide is not yet FDA approved as of this writing. Researchers are actively studying long-term effects on bone density, cardiovascular outcomes over extended follow-up, and lean muscle preservation during the fat loss process which are questions that any compound producing results this significant is obligated to answer before wide clinical use.
The Bigger Picture
What this generation of research has established is that obesity, metabolic disease, and the hunger and blood sugar dysregulation that drive them are biological problems not behavioral ones. The system that regulates how your body manages energy was always supposed to work, and in many people, it does not work the way it should, for reasons that have nothing to do with effort or discipline. These compounds do not override the body. They restore a signal the body already knows how to use. What you need to understand is the difference between these three generations, what each one targets, what the research has found, and where the science currently stands.
Disclaimer: This article is intended for informational and educational purposes only. It is not medical advice, diagnosis, treatment, or a recommendation regarding any peptide or wellness compound. Individuals should conduct their own research and consult qualified healthcare professionals regarding personal health decisions.
Sound familiar?
Over 4 million people have had the same lightbulb moment.
Morning Brew is a free daily newsletter that breaks down what's happening in business, finance, and tech — clearly, quickly, and with enough personality to make it the best email in your inbox.
No yelling. No filler. Just the news, finally making sense.